Hypertrophic cardiomyopathy: Difference between revisions
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 11: | Line 11: | ||
'''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com] {{AE}} {{Soroush}} | '''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com] {{AE}} {{Soroush}} | ||
{{SK}} Hypertrophic cardiomyopathy or HCM, Asymmetric septal hypertrophy or ASH, Hypertrophic obstructive cardiomyopathy, HOCM, Idiopathic hypertrophic subaortic stenosis or IHSS, familial isolated hypertrophic obstructive cardiomyopathy, familial isolated hypertrophic subaortic stenosis, familial | {{SK}} Hypertrophic cardiomyopathy or HCM, Asymmetric septal hypertrophy or ASH, Hypertrophic obstructive cardiomyopathy, HOCM, Idiopathic hypertrophic subaortic stenosis or IHSS, familial isolated hypertrophic obstructive cardiomyopathy, familial isolated hypertrophic subaortic stenosis, familial hypertrophic subaortic stenosis, idiopathic hypertrophic subaortic stenosis, familial hypertrophic obstructive cardiomyopathy, idiopathic hypertrophic obstructive cardiomyopathy, primitive hypertrophic obstructive cardiomyopathy, primitive hypertrophic subaortic stenosis, muscular subaortic stenosis, apical hypertrophic cardiomyopathy, which is also known as nonobstructive hypertrophic cardiomyopathy and Japanese variant hypertrophic cardiomyopathy or Yamaguchi syndrome. | ||
==[[Hypertrophic cardiomyopathy overview|Overview]]== | ==[[Hypertrophic cardiomyopathy overview|Overview]]== | ||
==[[Hypertrophic cardiomyopathy historical | ==[[Hypertrophic cardiomyopathy historical perspective|Historical Perspective]]== | ||
==[[Hypertrophic cardiomyopathy classification|Classification]]== | ==[[Hypertrophic cardiomyopathy classification|Classification]]== | ||
| Line 34: | Line 34: | ||
==Treatment== | ==Treatment== | ||
*'''Medical therapy''', '''Interventions, Surgery, Primary Prevention, Secondary Prevention, Cost Effectiveness of Therapy, Future or Investigational Therapy'''<br /> | *'''[[Hypertrophic cardiomyopathy medical therapy|Medical therapy]]''', '''[[Hypertrophic cardiomyopathy interventions|Interventions]], [[Hypertrophic cardiomyopathy surgery|Surgery]], [[Hypertrophic cardiomyopathy primary prevention|Primary Prevention]], [[Hypertrophic cardiomyopathy secondary prevention|Secondary Prevention]], Cost Effectiveness of Therapy, Future or Investigational Therapy'''<br /> | ||
==Resources== | ==Resources== | ||
Latest revision as of 18:35, 11 March 2020
For patient information click here
| Hypertrophic cardiomyopathy | |
 | |
|---|---|
| Hypertrophic cardiomyopathy. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy On the Web |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Synonyms and keywords: Hypertrophic cardiomyopathy or HCM, Asymmetric septal hypertrophy or ASH, Hypertrophic obstructive cardiomyopathy, HOCM, Idiopathic hypertrophic subaortic stenosis or IHSS, familial isolated hypertrophic obstructive cardiomyopathy, familial isolated hypertrophic subaortic stenosis, familial hypertrophic subaortic stenosis, idiopathic hypertrophic subaortic stenosis, familial hypertrophic obstructive cardiomyopathy, idiopathic hypertrophic obstructive cardiomyopathy, primitive hypertrophic obstructive cardiomyopathy, primitive hypertrophic subaortic stenosis, muscular subaortic stenosis, apical hypertrophic cardiomyopathy, which is also known as nonobstructive hypertrophic cardiomyopathy and Japanese variant hypertrophic cardiomyopathy or Yamaguchi syndrome.
Overview
Historical Perspective
Classification
Pathophysiology
Differentiating Hypertrophic Cardiomyopathy from Other Diseases
Causes
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice| History and Symptoms | Physical examination | Laboratory findings | Electrocardiogram | X Ray | Echocardiography and Ultrasound | CT Scan | MRI |Other Imaging Findings | Other Diagnostic Studies.
Treatment
- Medical therapy, Interventions, Surgery, Primary Prevention, Secondary Prevention, Cost Effectiveness of Therapy, Future or Investigational Therapy